Evidence map›Paper›PMID 32929164›Full record

ArticleScientific reports2020

Understanding and predicting ciprofloxacin minimum inhibitory concentration in Escherichia coli with machine learning.

Bálint Ármin Pataki, Sébastien Matamoros, Boas C L van der Putten, Daniel Remondini, Enrico Giampieri, Derya Aytan-Aktug, Rene S Hendriksen, Ole Lund, István Csabai, Constance Schultsz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Metabolism-Based Biomarkers for Rapid Phenotypic Antibiotic Susceptibility Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. How AI can help us beat AMR.npj antimicrobials and resistance · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. PredictingMicroorganisms · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 15 institutions in 11 countries.

Bálint Ármin PatakiDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Budapest, Hungary. patbaa@caesar.elte.hu.
Sébastien MatamorosDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Boas C L van der PuttenDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Daniel RemondiniDepartment of Physics and Astronomy (DIFA), University of Bologna, Bologna, Italy.
Enrico GiampieriDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
Derya Aytan-AktugNational Food Institute, Technical University of Denmark, Lyngby, Denmark.
Rene S HendriksenNational Food Institute, Technical University of Denmark, Lyngby, Denmark.
Ole LundDepartment of Bioinformatics, Technical University of Denmark, Lyngby, Denmark.
István CsabaiDepartment of Physics of Complex Systems, ELTE Eötvös Loránd University, Budapest, Hungary.
Constance SchultszDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
SPS COMPARE ML-AMR group
Eötvös Loránd University · HUTechnical University of Denmark · DKEuropean Bioinformatics Institute · GBAmsterdam University Medical Centers · NLAntwerp University Hospital · BERobert Koch Institute · DEToho University · JPUniversity of Bologna · ITAmsterdam Institute for Global Health and Development · NLAnimal and Plant Health Agency · GBFondation Mérieux · FRStatens Serum Institut · DKCenter for Veterinary Medicine · USErasmus MC · NLOxford University Clinical Research Unit · VN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is important that antibiotics prescriptions are based on antimicrobial susceptibility data to ensure effective treatment outcomes. The increasing availability of next-generation sequencing, bacterial whole genome sequencing (WGS) can facilitate a more reliable and faster alternative to traditional phenotyping for the detection and surveillance of AMR. This work proposes a machine learning approach that can predict the minimum inhibitory concentration (MIC) for a given antibiotic, here ciprofloxacin, on the basis of both genome-wide mutation profiles and profiles of acquired antimicrobial resistance genes. We analysed 704 Escherichia coli genomes combined with their respective MIC measurements for ciprofloxacin originating from different countries. The four most important predictors found by the model, mutations in gyrA residues Ser83 and Asp87, a mutation in parC residue Ser80 and presence of the qnrS1 gene, have been experimentally validated before. Using only these four predictors in a linear regression model, 65% and 93% of the test samples' MIC were correctly predicted within a two- and a four-fold dilution range, respectively. The presented work does not treat machine learning as a black box model concept, but also identifies the genomic features that determine susceptibility. The recent progress in WGS technology in combination with machine learning analysis approaches indicates that in the near future WGS of bacteria might become cheaper and faster than a MIC measurement.

Indexed as

Drug Resistance, BacterialGenes, BacterialMachine LearningAnti-Bacterial AgentsCiprofloxacinDNA GyraseEscherichia coliEscherichia coli ProteinsInhibitory Concentration 50Intracellular Signaling Peptides and ProteinsMutationToxicity TestsAnti-Bacterial AgentsCiprofloxacinDNA GyraseEscherichia coli ProteinsIntracellular Signaling Peptides and ProteinsqnrS1 protein, E coli

Identifiers

PMID32929164
PMCPMC7490380
OpenAlexW3085884784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.